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Abstract One of the characteristics of many neurodegenerative
diseases is the disruption of normal iron homeostasis in the brain.
Recent experimental work indicates that nanoscale magnetic
biominerals (primarily magnetite and maghemite) may be
associated with senile plaques and tau filaments found in brain
tissue affected by these diseases. These findings have important
implications for our understanding of the role of iron in
neurodegenerative disease as well as profound implications for
their causes. In addition, the presence of biogenic magnetite in
affected tissue should also provide improved mechanisms for
early detection through the modification of MRI pulse
sequences. ß 2001Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction and background
Though iron plays an important role in virtually all living
organisms ^ primarily through electron transport due to its
ability to change valence ^ it has a rather limited bioavailabil-
ity and, in some situations, it also can be toxic to cells. For
this reason, it is necessary for organisms to sequester iron in a
non-toxic form. In the human body (including the brain), as
well as in most organisms, iron is stored primarily in the core
of the iron storage protein ferritin. The ferritin protein is a
hollow spheroid shell 12 nm in diameter made up of 24 sub-
units. The central void in the shell is 8 nm in diameter and is
normally occupied by the iron biomineral ferrihydrite ^ a
hydrated iron oxide (5Fe2O3W9H2O) which generally contains
only Fe(III). It is in this form that most of the iron in the
body is stored.
In humans disruption of normal iron metabolism in the
brain is a characteristic of several neurodegenerative disorders
such as Alzheimer’s disease (AD), Parkinson’s disease (PD)
and progressive supranuclear palsy (PSP). For example, excess
iron accumulation is known to occur in AD patients ^ partic-
ularly in AD plaques (e.g. [1]) and total iron levels are ele-
vated in the hippocampus, amygdala, nucleus basalis of Mey-
nert and the cerebral cortex [2,3]. These elevated iron levels in
neurodegenerative tissue, however, do not correlate with ele-
vated levels of ferritin or the extracellular iron transport pro-
tein transferrin [3]. In fact, in several regions of the brains of
AD and PD patients, a reduction in transferrin, indicating
reduced mobility and sequestration of iron, has been reported
[3,4].
Recent studies have shown that various forms of iron may
play a signi¢cant role in the biochemical processes which lead
to the progression of these diseases. This is primarily thought
to be a result of oxidative stress ^ the generation of free
radicals via the Fenton reaction [5^8]. However, other results
also suggest that ferritin may act to modulate the formation
of tau ¢laments in PSP [9] (though there are no reliable in-
dications of abnormal ferritin levels in neurodegenerative tis-
sue) and that iron may promote aggregation of betaA4 [10].
Though the association of anomalous concentrations of
iron with neurodegenerative tissue is well documented, partic-
ularly in AD, methods for assaying iron in diseased tissue
generally are ion speci¢c, have poor spatial resolution and
provide little reliable quantitative information [11]. Recently,
some progress has been made in high-resolution iron analysis
of AD tissue by Smith and others [7,8]. They have shown,
using modi¢ed iron staining techniques, that redox-active
iron is closely associated with AD plaques and neuro¢brillary
tangles. This work also has demonstrated that lesion-associ-
ated iron is distinct from iron sequestered in ferritin and has
provided indirect evidence of the presence of Fe(II) in AD
tissue.
Though this technique o¡ers improved resolution, it is still
not possible to identify the structural form of the iron or to
map Fe(II) distribution. As such, iron anomalies associated
with neurodegenerative disease are not well characterized and
the structural/molecular form of the excess iron in AD
plaques and neurodegenerative tissue in general, is not known.
Research in this ¢eld is, however, beginning to shed light on
the role of iron. For example, work published last year has
demonstrated the further strengthened connection between
high levels of iron in the basal ganglia and oxidative stress
in Parkinson’s patients [12]. A disruption of iron metabolism
and increased iron in this same region of the brain also has
been implicated in AD and Huntington’s disease [13]; and
iron accumulation has been associated with microgliosis and
correlated with increased damage to the CA1 region of the
hippocampus via iron^zinc interactions in models of neurode-
generative diseases [14].
It should be noted, however, that some results have shown
that the presence of oxidized nucleosides in neurons does not
appear to be related to senile plaque material or neuro¢bril-
lary tangles in AD [15], though there are indications that iron
0014-5793 / 01 / $20.00 ß 2001Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 3 8 6 - 9
*Fax: (44)-1782-717 079. E-mail: jdobson@keele.ac.uk
FEBS 24816 1-5-01
FEBS 24816 FEBS Letters 496 (2001) 1^5
is a signi¢cant source of oxidative damage in AD [8]. In some
cases, free radical damage may even be reduced by AL depo-
sition due to the inhibitory role of AL-related Zn2 in H2O2-
mediated toxicity [16,17].
Though ferritin is the primary mechanism for iron storage
in the brain, over the past decade experimental work has
demonstrated the presence of another form of iron in human
brain tissue ^ biogenic magnetite (Fe3O4). Some of the poten-
tial consequences of the presence of magnetite in neurodegen-
erative disease tissue will be examined here.
2. Biogenic magnetite in the human brain
Biogenic magnetite, along with maghemite (QFe2O3, an ox-
idation product of magnetite with very similar magnetic prop-
erties which is likely produced by oxidation of magnetite dur-
ing ex vivo tissue handling), were ¢rst discovered in human
brain tissue in 1992 by a group at the California Institute of
Technology led by Joseph Kirschvink [18]. This work concen-
trated on studies of human brain tissue samples taken from
cadavers and proved somewhat controversial.
In order to examine the possibilities of contamination and
post mortem changes in brain chemistry, our group undertook
a series of studies on tissue removed from the human hippo-
campus [19]. As these examinations were performed on tissue
resected during amygdalohippocampectomies (a surgical pro-
cedure in which the damaged hippocampus of focal epilepsy
patients is removed) as well as cadaver tissue, post mortem
artefacts could be controlled. The results demonstrate clearly
that biogenic magnetite is present in human brain tissue and
con¢rm Kirschvink’s earlier results [20^22].
Magnetite is a ferrimagnetic iron oxide with alternating
lattices of Fe(II) and Fe(III) which are antiferromagnetically
coupled. This alternation of lattices and their corresponding
di¡erences in the number of unpaired electron spins give mag-
netite its strong magnetization. Since the discovery of magnet-
ite in the human brain, particles of this material have been
extracted, imaged and characterized both magnetically and
morphologically through transmission electron microscopy
(TEM) (see Fig. 1) and superconducting quantum interference
device (SQUID) magnetometry [18^24].
The particles are generally smaller than 200 nm and, in
most cases, are on the order of a few tens of nanometers.
While some particles exhibit dissolution edges, others preserve
pristine crystal faces and all particles examined thus far are
chemically pure (this is common in biogenic magnetite). Mor-
phologically, the particles are similar to those observed in
magnetotactic bacteria (e.g. [25]) and magnetic analysis of
bulk tissue samples indicates that the particles are likely
present in magnetically interacting clusters.
Unfortunately, up to now these particles have only been
observed in tissue extracts and we are currently developing
new techniques for imaging the particles in tissue slices and
mapping their distribution to tissue structures.
3. Ferritin as a magnetite precursor?
The ferrihydrite core of ferritin is capable of safely storing
up to 4500 iron atoms which, under normal circumstances, are
rendered unreactive with other molecules within the cell due
to the protein cage barrier [26]. Iron is moved into and out of
the ferritin shell through 3-fold and 4-fold channels between
the protein’s subunits. Sequestration is thought to be primar-
ily an oxidative process as highly toxic Fe(II) is taken into the
protein and oxidized to be stored as less toxic Fe(III) in the
form of ferrihydrite [27]. As the amount of iron stored in the
ferritin core is somewhat variable, the increases in iron ob-
served during histological examination of neurodegenerative
tissue may be due to increases in the number of iron atoms
stored in the core of the protein.
While an increase in the number of iron atoms in the ferri-
tin core may account for some of the excess iron observed in
histological examinations, another form of iron appears to be
present which could have signi¢cant consequences for neuro-
degenerative disease progression and early detection. If the
ferritin core becomes overloaded or there is a breakdown in
the protein’s function, a mechanism for Fe(II) oxidation is
lost. This process could lead to the formation of biogenic
magnetite, which is more strongly magnetic (ferrimagnetic)
than ferrihydrite (a superparamagnetic antiferromagnet at
body temperature) and contains alternating lattices of toxic
Fe(II) and less toxic Fe(III).
Fig. 1. TEM micrograph of biogenic magnetite extracted from the human hippocampus (¢gure after Schultheiss-Grassi et al., 1999).
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4. Potential consequences of biogenic magnetite in
neurodegenerative tissue
Preliminary experimental studies by our group and the
group of Dr. Carmen Quintana at the Instituto de Microelec-
tronica de Madrid, suggest that this biogenic magnetite may
be present in AD plaques, senile plaques and aberrant tau
¢laments extracted from PSP tissue [28]. In addition, magnetic
analyses of relatively large (several grams) samples of AD
tissue by Kirschvink’s group indicate the presence of magnet-
ite and/or maghemite, though the plaques were not analyzed
separately [18].
In 1995 we used magnetic force microscopy (MFM) to ex-
amine a sample of hippocampal tissue which contained plaque
material [20]. This opaque material exhibited a dipole-like
response, consistent with the presence of magnetic material
such as magnetite and/or maghemite (both have similar mag-
netic properties) (Fig. 2). Ferritin, which is superparamagnetic
(i.e. does not behave like a ‘magnet’ at body temperature),
would not produce such a response.
In late 1999 Dr. Quintana’s group used high-resolution
transmission electron microscopy and electron energy loss
spectroscopy to examine ferritin in paired helical ¢laments
from AD tissue and ferritin bound to aberrant tau ¢laments
in neurodegenerative progressive supranuclear palsy. The re-
sults give a preliminary indication of the presence of a cubic
iron oxide within the ferritin protein cage with spectra similar
to synthetic magnetite/maghemite standards [28]. As discussed
previously, it is possible that ferritin may act as a precursor
for the formation of biogenic magnetite in humans, perhaps
through excess loading of iron in the core and the breakdown
of normal protein function. This is supported by the evidence
for magnetite inside the ferritin protein cage.
If the presence of biogenic magnetite in AD plaques and
neurodegenerative tissue is con¢rmed, it could have important
consequences for our understanding of neurodegenerative dis-
ease progression ^ possibly even initiation ^ and could allow
early detection and diagnosis.
Biogenic magnetite may play a role in the progression and
initiation of neurodegenerative disease through free radical
production leading to tissue damage at the site of magnetite
accumulation. High levels of free iron in AD-a¡ected brain
tissue already have been noted as a possible cause of neuron
degeneration through free radical processes via the Fenton
reaction [5,29]. Magnetite and maghemite nanoparticles, how-
ever, also have been shown to have a substantial e¡ect on free
radical generation [30,31]. Recent experimental results also
have demonstrated that iron^oxygen complexes may be a
more e¡ective catalyst for free radical damage in brain tissue
than the Fenton reaction [32].
Fig. 2. Magnetic force microscope scan of plaque material from the human hippocampus showing a dipole-like magnetic response. (Figure after
Dunn et al., 1995, [20].)
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These e¡ects are achieved through strong, local magnetic
¢elds generated by biogenic magnetite particles which stabilize
triplet states during biochemical reactions taking place near-
by. This leads to the production of membrane-damaging free
radicals and changes in reaction yields (e.g. [33]). Even rela-
tively weak magnetic ¢elds can have a strong in£uence on
reaction yields [34]. In addition, Fe(II) in magnetite can be
readily oxidized (forming maghemite) and this process, to-
gether with local magnetic ¢eld e¡ects, may in£uence L-amy-
loid production and aggregation. This is particularly relevant
considering studies showing that iron promotes aggregation of
L-amyloid peptides in vitro and that L-amyloid potentiates
free radical formation by stabilizing ferrous iron [10,35].
5. Biogenic magnetite and early detection of
neurodegenerative disease
In addition to potential implications for disease progres-
sion, there are also possible bene¢ts to the presence of mag-
netite in neurodegenerative tissue. Early detection is one of
the primary goals of neurodegenerative research e¡orts and
one of the methods being considered at present is the use of
MRI. Usually, in more advanced patients, MR images exhibit
regions of hyperintensity due to atrophy in the a¡ected area of
the brain (e.g. [36]). While this method can be successful in
identifying neurodegenerative diseases such as Alzheimer’s
disease, by the time it is observed the disease has already
progressed signi¢cantly from its early stages.
Several authors, however, have reported the appearance of
hypointensity artefacts in T2-weighted MR images of di¡erent
areas of the human brain. Such artefacts have been observed
in MRI studies of patients su¡ering from age-related neuro-
degenerative diseases, particularly Parkinson’s disease and
AD [37^39]. High-¢eld (3 Tesla) MRI analysis of patients
with various stages of Parkinsonian symptoms has even re-
vealed a strong correlation between the severity of the symp-
toms and proxy measures of iron concentration based on T2*
values [39]. However, Chen and others have demonstrated
that hypointensity artefacts do not correlate with excess levels
of ferritin in the brain [40].
It is possible that these hypointensity artefacts may be ex-
plained by the e¡ects of strong local magnetic ¢elds generated
by clusters of magnetite/maghemite in AD plaques and neu-
rodegenerative tissue [18]. The mechanisms by which such
artefacts could occur are well understood and biocompatible
synthetic magnetite nanoparticles have been used as contrast
agents in MRI (e.g. [41,42]). In addition, major advances in
MRI technology already have been made which enable the
quantitative mapping of iron by MRI methods [43]. If bio-
genic magnetite is present in AD plaques and neurodegener-
ative tissue, these methods could be adapted to look for re-
gions of magnetite accumulation in subjects who may be pre-
disposed to these diseases. This could lead to techniques for
detection of neurodegenerative disease at a much earlier stage
than is currently possible rather than imaging atrophied tissue
already in the advanced stages of the disease.
6. Discussion
Histological examinations have shown consistently that ex-
cess iron is associated with pathological tissue in neurodegen-
erative diseases. As these increases in iron are not necessarily
correlated to increases in ferritin, another form of iron is
likely present. Experimental results thus far indicate that the
accumulation of excess iron in this tissue has likely resulted in
the formation of biogenic magnetite and or maghemite.
The presence of biogenic magnetite in AD plaques could
have far-reaching consequences for our understanding of the
disease. Though this material has not been observed ^ either
directly or indirectly ^ speci¢cally in AD plaques, there is
ample reason to believe that it is probably there:
b Magnetite and maghemite are certainly present in other
regions of the brain and the concentrations, packing geom-
etries and grain sizes vary considerably.
b Iron levels in AD plaques cannot be adequately explained
by increases in ferritin or transferrin.
b Preliminary experimental evidence indicates that some brain
plaque material is magnetic and that some AD ferritin may
contain magnetite.
b Magnetic analyses of relatively large AD tissue samples
indicate the presence of magnetite and/or maghemite.
If magnetite is present in neurodegenerative tissue, this
should lead to a better understanding of the role of this ma-
terial in these diseases and may provide a mechanism for early
detection and diagnosis of diseases that are notoriously di⁄-
cult to diagnose at an early stage.
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